Overview


According to FutureWise analysis, the market for Diabetic Kidney Disease is expected to grow with a CAGR of 5.35% over the forecast period 2024-2032, and reach a market value of US$ 3.99 billion by 2031.

Diabetic Kidney Disease is a condition that arises from longstanding, uncontrolled diabetes. It is the foremost cause of chronic kidney disease (CKD) worldwide. It develops over time due to the damaging consequences of high blood sugar levels on the kidneys. The condition primarily affects individuals with either Type 1 or Type 2 diabetes. Prolonged exposure to elevated blood sugar levels puts pressure on the kidneys, which filter waste products from the blood. It is a progressive condition that worsens over time. Initially, there may be no noticeable symptoms, but it can lead to significant kidney dysfunction as it increases. Several factors increase the risk of developing DKD, such as poor glycemic control (high blood sugar levels), high blood pressure, genetic predisposition, smoking, and certain lifestyle habits.

Some common treatments for diabetic kidney disease are angiotensin receptor blockers (ARBs), such as losartan, irbesartan, and valsartan, which are a class of drugs that help relax the blood vessels, thereby reducing blood pressure. They also have specific benefits in protecting the kidneys from further damage in DKD. Angiotensin-converting enzyme (ACE) Inhibitors are similar to ARBs, ACE inhibitors like enalapril, lisinopril, and ramipril help relax blood vessels and lower blood pressure. They also have kidney-protective effects and are often used in conjunction with ARBs.

FutureWise Market Research has published a report that provides an insightful analysis diabetic kidney disease market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts diabetic kidney disease market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • AstraZeneca 
  • Pfizer Inc 
  • Allergan,Inc
  • Bristol-Myers Squibb Company
  • Endo International plc
  • Dr. Reddy's Laboratories Ltd 
  • Sun Pharmaceutical Industries Ltd 
  • Teva Pharmaceutical Industries Ltd 
  • Novartis AG
  • Mylan NV 
  • CiplaInc 
  • Lupin 
  • Aurobindo Pharma 
  • Sanofi 
  • Fresenius SE & Co. KGaA 
  • F. Hoffmann-La Roche Ltd 
  • Takeda Pharmaceutical Company Limited 

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Diabetic Kidney Disease Market:

  • In August 2022, Bayer launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with diabetic kidney disease (DKD) associated with type 2 diabetes. This drug is designed to address the unique challenges of type 2 diabetes and kidney disease, offering a targeted therapeutic approach for individuals facing this dual condition. It represents a significant advancement in managing DKD, providing a favorable option for patients seeking to reduce the progression of kidney damage associated with diabetes.

The increasing global prevalence of diabetes stands as a primary impetus propelling the Diabetic Kidney Disease (DKD) market. Diabetes constitutes a substantial risk factor for developing kidney disease, creating a direct and symbiotic relationship between the two conditions. As the diabetic population continues to surge worldwide, the incidence of DKD is expected to parallelly escalate. This surge in diabetic cases amplifies the pool of individuals at risk for DKD. It underscores the pressing need for advanced diagnostics, therapeutics, and interventions in the DKD market, thereby driving its growth trajectory. In addition, the increasing geriatric population is expected to drive the demand for the diabetic kidney disease market. With age comes an increased susceptibility to diabetes and kidney disease, creating a synergistic effect. As the global population ages, there is a heightened probability of individuals concurrently wrestling with these conditions. This demographic shift amplifies the prevalence of DKD but also accentuates the urgency for comprehensive treatment and management solutions. Consequently, this demographic trend is predicted to significantly fuel the rising demand for effective DKD treatment over the forecast period. Also, the growth of retail and online pharmacies presents a substantial opportunity in the market. These platforms serve as accessible and convenient channels for patients to procure essential medications and treatments for DKD. With the increasing adoption of e-commerce and digital health solutions, individuals with DKD may now easily access a wide range of pharmaceuticals, enhancing drug adherence and overall disease management. However, the high cost of diabetic kidney disease treatment, encompassing expenses for medications, dialysis, and potential kidney transplants, may pose a challenging obstacle. The high costs associated with managing DKD may render it financially difficult for certain patients, potentially hindering market growth. Further, a lack of awareness among individuals with diabetes regarding the risk of developing kidney disease, coupled with the frequently asymptomatic nature of early-stage DKD, may lead to delayed diagnosis and intervention. This delayed recognition and treatment impact patient outcomes and impede the market's expansion.

By Type

  • Type 1 Diabetes
  • Type 2 Diabetes

By Treatment

  • Angiotensin Receptor Blockers (ARBs)
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Antioxidant Inflammation Modulator
  • Calcium Channel Blockers
  • Others

By Distribution Channel

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the rise in kidney-related disorders, rising government and pharmaceutical organization efforts to raise awareness of kidney disease, the existence of generic manufacturers, the rising awareness surge in a number of geriatric populations suffering from diabetic nephropathy, and well-developed healthcare infrastructure in the US is anticipated to drive the growth of the market. Moreover, rising R&D efforts, the presence of key players, product approvals and development, partnership and collaboration, increased use of combination drugs, and increasing patient population in the region are further expected to propel the market over the forecast period. For instance, in April 2021, Farxiga was approved in the US for the treatment of diabetic kidney diseases in individuals at risk of progression with and without type-2 diabetes.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Diabetic Kidney Disease Market By Type, By Treatment, By Distribution Channel, and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Diabetic Kidney Disease Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Diabetic Kidney Disease Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Diabetic Kidney Disease Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Diabetic Kidney Disease Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Type 1 Diabetes
      2. Type 2 Diabetes
  • 8.  Diabetic Kidney Disease Market, By Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Angiotensin Receptor Blockers (ARBs)
      2. Angiotensin-Converting Enzyme (ACE) Inhibitors
      3. Antioxidant Inflammation Modulator
      4. Calcium Channel Blockers
      5. Others
         
  • 9.  Diabetic Kidney Disease Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Online Pharmacy
      2. Hospital Pharmacy
      3. Retail Pharmacy
  • 10.  North America Diabetic Kidney Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Diabetic Kidney Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Diabetic Kidney Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Diabetic Kidney Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. AstraZeneca 
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Pfizer Inc 
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Allergan,Inc 
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Bristol-Myers Squibb Company 
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Endo International plc
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Dr. Reddy's Laboratories Ltd
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Sun Pharmaceutical Industries Ltd
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Teva Pharmaceutical Industries Ltd
          8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Novartis AG
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Mylan NV 
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. CiplaInc 
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Lupin
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Aurobindo Pharma 
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Sanofi 
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Fresenius SE & Co. KGaA 
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. F. Hoffmann-La Roche Ltd
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Takeda Pharmaceutical Company Limited
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients